Eugene

[email protected]

LATEST

Novo Nordisk, Dicerna in $675-M-Plus Deal for RNAi Therapies
By

By
Novo Nordisk and Dicerna Pharmaceuticals, a biopharmaceutical company specializing in ribonucleic acid interference (RNAi) therapies, have formed a collaboration to discover and develop therapies for treating liver-related cardio-metabolic diseases, in…

BMS Completes $74-Billion Acquisition of Celgene
By

By
Bristol-Myers Squibb (BMS) has completed its $74-billion acquisition of Celgene following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April…

AGC Biologics, Thermo Fisher Expand; Recipharm Divests Bioanalysis Business
By

By
The latest news from CDMOs, CMOs, and suppliers featuring news from AGC Biologics, Thermo Fisher Scientific, Recipharm, Aptar, West, Schott, and Heraeus. Chemicals/Chemical API Manufacturing China’s Raybow Acquires US-Based API…

Fujifilm To Invest $120 Million in Gene-Therapy Labs and Mfg for CDMO Business
By

By
Fujifilm plans to invest approximately JPY 13 billion ($120 million) in gene-therapy laboratories and manufacturing for its contract development and manufacturing business. The investment will include the addition of dedicated…

Lupin To Sell Stake in Kyowa Pharmaceutical for $527 Million
By

By
Lupin a Mumbai, India-based pharmaceutical company, has agreed to sell its entire stake in its Japanese subsidiary, Kyowa Pharmaceutical Industry Co., for JPY 57.4 billion ($527 million) to the private-equity…

Global Pharma Briefs: News from Asia and the US
By

By
A roundup of developments and latest news from India (Aurobindo, Biocon) and the US (Cosette Pharmaceuticals). India FDA Issues Form 483 to Aurobindo API Mfg Facilities in India The US…

FDA OKs Celgene’s Rare-Disease Anemia Drug
By

By
The US Food and Drug Administration (FDA) has approved Celgene’s and Acceleron’s Pharma Reblozyl (luspatercept-aamt) for treating anemia in adult patients with beta thalassemia, a rare blood disorder, who require…

Sandoz To Acquire Aspen Pharmacare’s Japanese Business in $440-M Deal
By

By
Novartis’ Sandoz has agreed to acquire the Japanese business of Aspen Global Inc. (AGI), a wholly owned subsidiary of the specialty and branded pharmaceutical company, Aspen Pharmacare, for up to…

Biogen in $310-Million Deal with Samsung Bioepis for Biosimilars
By

By
Biogen has proposed a new $310-million transaction with Samsung Bioepis, a biosimilar biopharmaceutical joint venture between Samsung BioLogics and Biogen, for the exclusive rights to commercialize two new ophthalmology biosimilars,…

AstraZeneca To Create New R&D and AI Centers, $1-Bn Joint Fund in China
By

By
AstraZeneca has announced three large-scale initiatives in China to advance global research and development (R&D) for innovative new medicines. The company is creating a new global R&D center and an…